探讨紫杉类方案化疗对乳腺癌患者血糖的影响

目的观察紫杉类方案化疗对乳腺癌患者血糖的影响。方法于2013年10月—2014年10月在该院门诊选取56例乳腺癌合并糖尿病患者,依据病情,要求其住院,入院后依照住院号尾号的奇偶数进行分组,分别为治疗组和对照组各28例,治疗组的28位乳腺癌合并有糖尿病患者采用紫杉类方案化疗;对照组28位乳腺癌患者采用嘧啶苯芥方案化疗。从而对比分析两组化疗方案对乳腺癌合并糖尿病患者血糖的影响。结果治疗组乳腺癌合并有糖尿病患者在采用紫杉类方案化疗后,乳腺癌合并有糖尿病患者的血糖降低,且对癌性细胞有抑制作用,总有效率100%;对照组乳腺癌合并糖尿病患者仅抑制癌性细胞的扩散,对血糖没有影响,总有效率78.6%。结论紫杉类方案化疗对乳腺癌糖尿病患者有降糖作用,适合于乳腺癌合并糖尿病患者的化疗,值得临床应用与推广。

帕妥珠单抗联合TP新辅助化疗方案对HER2阳性乳腺癌患者的影响分析

目的:探讨帕妥珠单抗联合紫杉类和铂类药物(TP)新辅助化疗方案对人表皮生长因子受体2(HER2)阳性乳腺癌患者免疫功能的影响及安全性分析.方法:选取2021年1月—2023年1月成武县人民医院收治的HER2阳性乳腺癌患者80例为研究对象,随机分为对照组和观察组,各40例.对照组采用TP新辅助化疗方案治疗,观察组在对照组基础上联合帕妥珠单抗治疗.比较两组治疗效果.结果:观察组肿瘤控制率高于对照组,差异有统计学意义(P=0.045);治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)水平高于治疗前,CD8^(+)水平低于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05);治疗后,两组半胱氨酸天冬氨酸蛋白酶-3、生存素水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:帕妥珠单抗联合TP新辅助化疗方案治疗HER2阳性乳腺癌有较好的肿瘤控制率,能改善机体免疫功能,调节乳腺组织凋亡分子平衡,且不会增加不良反应发生率.

Role of taxanes in pancreatic cancer

Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.